The FDA’s decision allows Abrysvo to be given to those who are 32 to 36 weeks into their pregnancy to prevent lower respiratory tract disease (LRTD) and severe LRTD in infants from birth until they are six months old.
RSV is a common contagious virus characterised by several mild, cold-like symptoms. Although most people recover within a week or two, the virus can cause severe illness in young infants, older adults and individuals with certain chronic medical conditions.
